MeSH tree: D12.776.124.790.651.114.224.060.469
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according ...
Jan 25, 2026
0
12
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.
Jun 2, 2025
0
25
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory ...
Apr 4, 2025
0
32
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92%, suggesting a new standard therapy for the disease. The New England Journal ...
Oct 16, 2024
1
75
Hodgkin's lymphoma (HL), impacting the lymph nodes and lymphatic system, has experienced a gradual increase in survival rates thanks to contemporary chemotherapy. However, challenges persist for patients who exhibit resistance ...
Aug 13, 2024
0
27
As novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along with how the treatment is working to extend survival. This is particularly true in young people with cancer ...
Aug 5, 2024
0
28
A new review paper titled "Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability" has been published in Oncotarget.
Dec 20, 2023
0
34
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly ...
Jun 4, 2023
0
120
A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led ...
Nov 3, 2022
0
104
